September 12, 2024
Research offers promising insights into the ideal frontline therapies for mantle cell lymphoma (MCL), but there are continued unmet needs in the relapsed/refractory setting, blood cancer […]
September 12, 2024
HOUSTON — Chimeric antigen receptor T-cell therapy (CAR T) has emerged as a game changer for the treatment of multiple myeloma (MM), but questions remain as […]
September 11, 2024
The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) is effective in extensive-stage small cell lung cancer (ES-SCLC), with a higher dose of the drug almost doubling the response […]
September 11, 2024
SAN DIEGO — Treatment with the estimated glomerular filtration rate (EGFR) tyrosine kinase inhibitor (TKI) aumolertinib after chemoradiation was associated significant improvement in progression-free survival compared […]
September 11, 2024
TOPLINE: Universal testing identified germline pathogenic variants in 7.3% of women with breast cancer, suggesting that traditional risk-based criteria may miss more than a third of […]
September 11, 2024
SAN DIEGO — The degree of event-free survival (EFS) after surgery in early-stage non–small cell lung cancer (NSCLC) depends on the amount of residual tumor, according […]
September 10, 2024
More than 30,000 people will descend on Barcelona, Spain, this week for the 2024 European Society for Medical Oncology (ESMO) Congress, which runs from September 13 […]
September 10, 2024
SAN DIEGO — Combination therapy with osimertinib and savolitinib could become a novel first-line treatment option for patients with de novo MET-aberrant, EGFR-mutated advanced non–small cell […]
September 10, 2024
TOPLINE: Patients with early-onset colorectal cancer (CRC) living in rural and impoverished areas face a significantly higher risk of dying from CRC. METHODOLOGY: Previous research has […]